10 Jan 2013 07:01
10 January 2013
Instem plc
("Instem", the "Company" or the "Group")
JOINN Laboratories China Purchases Provantis
Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, announces today that JOINN Laboratories (JOINN) has purchased its Provantis® preclinical software solution suite to automate processes within its China-based facilities located in Beijing and Suzhou.
JOINN provides drug screening, efficacy studies, pharmacokinetics studies, safety evaluations, clinical trials and final drug registration services. Founded in 1995, JOINN was China's first preclinical laboratory to be inspected by the U.S. Food and Drug Administration (FDA) for Good Laboratory Practice (GLP) compliance, and now supports clients from more than 20 provinces across China, Japan and Europe. Within the United States, JOINN provides international clients with technical consulting services for FDA drug registration.
Following a comprehensive evaluation of software technologies, Instem was selected due to its presence and experience within China and its leading position in the global early development safety assessment market. Utilising Provantis, JOINN will further improve the quality of its study processes and deliver demonstrable efficiency improvements in support of its mission to provide services for drug innovation to benefit worldwide public health.
Provantis is a modern, fully integrated software system for single users and global organisations engaged in preclinical evaluation studies. Orchestrating every facet of preclinical drug safety assessment, Provantis streamlines processes and workflows with straightforward, intuitive functionality for simple or complex studies within a GLP or non-GLP environment, on-site or over the Web.
Phil Reason, CEO of Instem plc, commented: "We are delighted to welcome JOINN, China's largest provider of preclinical studies, to the Instem client community. Their order for 200 licensed users adds significantly to the leadership position we already enjoy in the China market and is a further indication of the longer term growth potential in what is already the third largest pharmaceutical market in the world."
For further information, please contact:
Instem plc | +44 (0) 1785 825 600 |
Phil Reason, CEO | |
Nigel Goldsmith, CFO | |
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
Aubrey Powell | |
Joe Stroud | |
Newgate Threadneedle | +44 (0) 20 7653 9850 |
Caroline Evans-Jones | |
Fiona Conroy |
About Instem plc
Instem is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.
Instem has over 130 customers in North America, Europe, China, India and Japan, including 16 of the top 20 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and has a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software, making Instem an ideal partner to help unlock the scientific/commercial value from these legacy repositories.
To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/